Dubai, UAE - Agiomix, the next generation genomics company has announced the appointment of a leading physician-scientist, Dr. Cengiz Yakicier to the position of Medical Director with immediate effect. As a member of Agiomix medical board Dr. Cengiz will be responsible for developing and executing on the company’s medical strategy to drive genomic analysis across healthcare practices in the region.
“We are very excited to welcome Dr. Cengiz to our team of medical experts. This is a transformative time in the evolution of precision and translational medicine and Dr. Cengiz will add a lot to our services to the healthcare community” said Dr. John Clarkson Board Director of Agiomix FZ-LLC.
For over three decades, Dr. Cengiz has worked at leading institutions throughout Asia, Europe and US; he currently serves as the Director of the Molecular Pathology Laboratory at Acıbadem in Istanbul. He is Founding Dean of Faculty of Science and Arts at Acıbadem University.
Dr. Cengiz holds an MD degree in Nuclear Medicine, he also holds Master’s and PhD degrees in Molecular Genetic from University Claude Bernard, Lyon, France, where he served as a research fellow; he also served as a research fellow at the Gastrointestinal Unit of Massachusetts General Hospital at Harvard Medical School in Boston, USA. Dr. Cengiz has numerous publications in renowned medical journals.
Dr. Cengiz said: “I am delighted to join the Agiomix Medical Board, I believe that Agiomix has the right lab infrastructure and medical expertise to provide truly outstanding and world-class genomics services, I am looking forward to adding value to Agiomix ability to analyze complex pathologies and produce excellent medical reports to aid in the diagnosis and management of disease.”
About Agiomix FZ-LLC
Agiomix FZ-LLC is a Dubai-headquartered genomics company, focused on offering sequencing and genotyping services to research and clinical customers. Agiomix strives to offer localized, high standard and affordable genomics analysis services with unparalleled counseling and support.
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
